NAT2 Polymorphism and Clinical Factors that Increase Antituberculosis Drug-Induced Hepatotoxicity

References

• Forget EJ , MenziesD. Adverse reactions to first-line antituberculosis drugs. Expert Opin Drug Saf.5(2), 231–249 (2006).
   PubMed Web of Science ®Google Scholar
• Lee FY , WongHS , ChanHKet al. Hepatic adverse drug reactions in Malaysia: an 18-year review of the national centralized reporting system. Pharmacoepidemiol. Drug Saf.29(12), 1669–1679 (2020).
   PubMed Web of Science ®Google Scholar
• Page KR , SifakisF , MontesDe Oca R et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis. Arch. Intern. Med.166(17), 1863–1870 (2006).
   PubMedGoogle Scholar
• Abbara A , ChittyS , RoeJKet al. Drug-induced liver injury from antituberculous treatment: a retrospective study from a large TB centre in the UK. BMC Infect. Dis.17(231), 1–9 (2017).
   PubMedGoogle Scholar
• Gezahegn LK , ArgawE , AssefaB , GeberesilassieA , HagaziM. Magnitude, outcome, and associated factors of anti-tuberculosis drug-induced hepatitis among tuberculosis patients in a tertiary hospital in north Ethiopia: a cross-sectional study. PLoS One15(11), e0241346 (2020).
   PubMed Web of Science ®Google Scholar
• Jiang F , YanH , LiangLet al. Incidence and risk factors of anti-tuberculosis drug induced liver injury (DILI): large cohort study involving 4652 Chinese adult tuberculosis patients. Liver Int.41, 1565–1575 (2021).
   PubMed Web of Science ®Google Scholar
• Soliman I , AhmadR , RajahJet al. Anti-tuberculous drug-induced hepatotoxicity: a retrospective look onto Abu-Dhabi tertiary health care center Sheikh Khalifa Medical City (SKMC) tuberculosis patients over a 7 years’ period. Br. J. Med. Med. Res.17(10), 1–9 (2016).
   Google Scholar
• eMahboub BH , VatsMG (Eds). Tuberculosis – current issues in diagnosis and management.IntechOpen, London, UK (2013).
   Google Scholar
• Hein DW , GrantDM , SimE. Update on consensus N-acetyltransferase gene nomenclature. Pharmacogenet. Genomics10(4), 291–292 (2000).
   Google Scholar
• Zang Y , DollMA , ZhaoS , StatesJC , HeinDW. Functional characterization of single nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2. Carcinogenesis28(8), 1665–1671 (2007).
   PubMed Web of Science ®Google Scholar
• Yuliwulandari R , SusilowatiRW , WicaksonoBDet al. NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis. J. Hum. Genet.61(6), 533–537 (2016).
   PubMed Web of Science ®Google Scholar
• Wattanapokayakit S , MushirodaT , YanaiHet al. NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients. Int. J. Tuberc. Lung Dis.20(10), 1364–1369 (2016).
   PubMed Web of Science ®Google Scholar
• Chan SL , ChuaAPG , AminkengFet al. Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients. PLoS One.12(10), e0186200 (2017).
   PubMed Web of Science ®Google Scholar
• Possuelo LG , CastelanJA , DeBrito TCet al. Association of slow n-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from southern Brazil. Eur. J. Clin. Pharmacol.64(7), 673–681 (2008).
   PubMed Web of Science ®Google Scholar
• An HR , WuXQ , WangZY , ZhangJX , LiangY. European Association for the Study of the Liver. NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients. Clin. Exp. Pharmacol. Physiol.39(6), 535–543 (2012).
   PubMed Web of Science ®Google Scholar
• Saukkonen JJ , CohnDL , JasmerRMet al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am. J. Respir. Crit. Care Med.174(8), 935–952 (2006).
   PubMed Web of Science ®Google Scholar
• Miller SA , DykesDD , PoleskyHF. A simple salting out procedure for extracting DNA from human nucleated cells. Nuc. Acids Res.16(3), 1215 (1987).
   Google Scholar
• Weckx S , Del-FaveroJ , RademakersRet al. novoSNP, a novel computational toll for sequence variation discovery. Genome Res.15(3), 436–442 (2005).
   PubMed Web of Science ®Google Scholar
• Stephens M , ScheetP. Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am. J. Hum. Genet.76(3), 449–462 (2005).
   PubMed Web of Science ®Google Scholar
• Ng CS , HasnatA , AlMaruf Aet al. N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group. Eur. J. Clin. Pharmacol.70(9), 1079–1086 (2014).
   PubMed Web of Science ®Google Scholar
• Stephens M , SmithNJ , DonnellyP. A new statistical method for haplotype reconstruction from population Data. Am. J. Hum. Genet.68(4), 978–989 (2001).
   PubMed Web of Science ®Google Scholar
• Sivapalan V , ZainSM , JinSet al. Impact of nitric oxide synthase 2 gene variant on risk of anti-tuberculosis drug-induced liver injury in the Malaysian population. Sains Malays.49(2), 237–248 (2020).
   Web of Science ®Google Scholar
• Bell DA , TaylorJA , ButlerMAet al. Genotype/phenotype discordance for human arylamine n-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African–Americans. Carcinogenesis14(8), 1689–1692 (1993).
   PubMed Web of Science ®Google Scholar
• Cavaco I , ReisR , GilJP , RibeiroV. CYP3A4*1B and NAT2*14 alleles in a native African population. Clin. Chem. Lab. Med.41(4), 606–609 (2003).
   PubMed Web of Science ®Google Scholar
• Lin HJ , HanCY , LinBK , HardyS. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics4(3), 125–134 (1994).
   PubMedGoogle Scholar
• Hein DW , DollMA , RustanTD , FergusonRJ. Metabolic cctivation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: effects of 7 specific NAT2 nucleic acid substitutions. Cancer Res.55(16), 3531–3536 (1995).
   PubMed Web of Science ®Google Scholar
• Bolt HM , SelinskiS , DannappelD , BlaszkewiczM , GolkaK. Re-investigation of the concordance of human NAT2 phenotypes and genotypes. Arch. Toxicol.79(4), 196–200 (2005).
   PubMed Web of Science ®Google Scholar
• Yuliwulandari R , PrayuniK , SusilowatiRWet al. NAT2 slow acetylator is associated with anti-tuberculosis drug-induced liver injury sverity in indonesian population. Pharmacogenomics20(18), 1303–1310 (2019).
   PubMed Web of Science ®Google Scholar
• Bose PD , SarmaMP , MedhiS , DasBC , HusainSA , KarP. Role of polymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis. J. Gastroenterol. Hepatol.26(2), 312–318 (2011).
   PubMed Web of Science ®Google Scholar
• Sharma S , JhaBK , SharmaAet al. Genetic polymorphism of N-acetyltransferase 2 and susceptibility to antituberculosis drug-induced hepatotoxicity. Indian J. Med. Res.114(6), 924–8 (2016).
   Google Scholar
• Santos NPC , Callegari-JacquesSM , DosSantos AKCRet al. N-acetyl transferase 2 and cytochrome P450 2E1 genes and isoniazid-induced hepatotoxicity in Brazilian patients. Int. J. Tuberc. Lung Dis.17(4), 499–504 (2013).
   PubMed Web of Science ®Google Scholar
• Teixeira RLDF , MoratoRG , CabelloPHet al. Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients. Mem. Inst. Oswaldo Cruz106, 716–724 (2011).
   PubMed Web of Science ®Google Scholar
• Leiro-Fernandez V , ValverdeD , Vázquez-GallardoRet al. N-acetyltransferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in Caucasians. Int. J. Tuberc. Lung Dis.15(10), 1403–1408 (2011).
   PubMed Web of Science ®Google Scholar
• Lv X , TangS , XiaYet al. NAT2 genetic polymorphisms and anti-tuberculosis drug induced hepatotoxicity in Chinese community population. Ann. Hepatol.11(5), 700–707 (2012).
   PubMed Web of Science ®Google Scholar
• Upton AM , MushtaqA , VictorTCet al. Arylamine N-acetyltransferase of Mycobacterium tuberculosis is a polymorphic enzyme and a site of isoniazid metabolism. Mol. Microbiol.42(2), 309–317 (2001).
   PubMed Web of Science ®Google Scholar
• Unissa AN , SukumarS , HannaLE. The role of N-acetyl transferases on isoniazid resistance from Mycobacterium tuberculosis and human: an in silico approach. Tuberc. Respir. Dis.80(3), 255–264 (2017).
   PubMedGoogle Scholar
• Yuliwulandari R , PrayuniK , RazariIet al. Genetic characterization of N-acetyltransferase 2 variants in acquired multidrug-resistant tuberculosis in Indonesia. Pharmacogenomics22(03), 157–163 (2021).
   PubMed Web of Science ®Google Scholar
• Fauzi AR , ShahA , RathorMY , SatwiS. Risk factors for anti tuberculous drugs induced hepatitis: a prospective survey from a chest clinic in a general hospital. Med. J. Malaysia59(1), 72–77 (2004).
   PubMedGoogle Scholar
• Marzuki OA , FauziARM , AyoubS , ImranMK. Prevalence and risk factors of anti-tuberculosis drug-induced hepatitis in Malaysia. Singapore Med. J.49(9), 688 (2008).
   PubMed Web of Science ®Google Scholar
• Sarda P , SharmaSK , MohanAet al. Role of acute viral hepatitis as a confounding factor in antituberculosis treatment induced hepatotoxicity. Indian J. Med. Res.129(1), 64–67 (2009).
   PubMed Web of Science ®Google Scholar
• Molla Y , WubetuM , DessieB. Anti-tuberculosis drug induced hepatotoxicity and associated factors among tuberculosis patients at selected hospitals, Ethiopia. Hepatic Med. Evid. Res.13, 1 (2021).
   PubMed Web of Science ®Google Scholar
• Song JH , YoonSY , ParkTYet al. The clinical impact of drug-induced hepatotoxicity on anti-tuberculosis therapy: a case–control study. Respir. Res.20(1), 1–8 (2019).
   PubMed Web of Science ®Google Scholar
• Zazzara MB , PalmerK , LiborioVetrano D , CarfìA , GrazianoO. Adverse drug reactions in older adults: a narrative review of the literature. Eur. Geriatr. Med.12, 463–473 (2021).
   PubMed Web of Science ®Google Scholar
• Zhao H , WangY , ZhangT , WangQ , XieW. Drug-induced liver injury from anti-tuberculosis treatment: a retrospective cohort study. Med. Sci. Monit.26, e920350 (2020).
   PubMed Web of Science ®Google Scholar
• Zucker I , PrendergastBJ. Sex differences in pharmacokinetics predict adverse drug reactions in women. Biol. Sex Differ.11(32), 1–14 (2020).
   PubMedGoogle Scholar
• Yew WW , ChanDP , LeungCCet al. Can toxicities induced by antituberculosis drugs be better managed in diabetic patients? Eur. Respir. J. 50(1), 1700409 (2017).
   PubMed Web of Science ®Google Scholar
• Yew WW , ChangKC , ChanDP. Oxidative stress and first-line antituberculosis drug-induced hepatotoxicity. Antimicrob. Agents Chemother.62(8), e02637–17 (2018).
   PubMed Web of Science ®Google Scholar
• Pukenyte E , LescureFX , ReyDet al. Incidence of and risk factors for severe liver toxicity in HIV-infected patients on anti-tuberculosis treatment. Int. J. Tuberc. Lung Dis.11(1), 78–84 (2007).
   PubMed Web of Science ®Google Scholar
• Yimer G , GryM , AmogneW , MakonnenE , HabtewoldA. Evaluation of patterns of liver toxicity in patients on antiretroviral and anti-tuberculosis drugs: a prospective four arm observational study in Ethiopian patients. PLoS One9(4), e94271 (2014).
   PubMed Web of Science ®Google Scholar
• Tostmann A , BoereeMJ , AarnoutseRE , de LangeWC , vander Ven AJ , DekhuijzenR. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J. Gastroenterol. Hepatol.23(2), 192–202 (2008).
   PubMed Web of Science ®Google Scholar